FIGARO trial

Chief investigator - Professor Charles Craddock, University Hospital Birmingham
A randomised trial of the FLAMSA-BU conditioning regimen in patients with acute myeloid leukaemia and myelodysplasia undergoing allogeneic stem cell transplantation
Amount awarded: £100,392
Award start date: 15 Nov 2013
Recruitment start date: 16 Oct 2013
Award duration: 4.5 years (60 months)

People with AML or MDS may have high dose chemotherapy – also called ‘conditioning’ - followed by an allogeneic stem cell transplant (when a person receives a stem cell transplant, sometimes called a bone marrow transplant, from a matched donor). To reduce side effects from high dose treatment, doctors may use lower doses of drugs. This is called reduced intensity conditioning.

But there is a risk that AML or MDS may come back after reduced intensity conditioning. So researchers are looking for new combinations of drugs to reduce the risk of the disease coming back without increasing side effects.

In this trial, researchers are looking at a reduced intensity conditioning regimen called FLAMSA-BU. It is made up of the chemotherapy drugs fludarabine, cytarabine, amsacrine and busulphan, as well as anti-thymocyte globulin (ATG) and mycophenolate mofetil, which damp down the immune system. Researchers think that this treatment could improve outcomes in older people because of reduced side effects and a lower risk of AML returning. FLAMSA-BU will be compared with standard intensity conditioning.

The aim of the trial is to:

  • See if outcomes are improved for people receiving FLAMSA-BU after their transplant compared with people who have other types of intensity conditioning treatment

This trial is closed for recruitment, and we hope to update you with the results soon.